GeoVax Unveils Promising COVID-19 Vaccine Data for Immunocompromised at EHA2025
GeoVax Labs presents GEO-CM04S1 vaccine data at EHA2025, showing promise for immunocompromised patients with superior immune response vs. mRNA vaccines.
This news is crucial as it highlights a potential breakthrough in COVID-19 vaccination for immunocompromised individuals, a group that has been particularly vulnerable due to inadequate immune responses to current vaccines. The development of GEO-CM04S1 could significantly improve protection for these patients, offering hope for better health outcomes and a step forward in the global fight against COVID-19.
